Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: GSK 10.595, Merck & Co. 16.607.
GSK vs Merck & Co. Net Worth and Market Cap
GSK (GSK) and Merck & Co. (MRK) are peers in Vaccines. GSK reported revenue of $10.6B as of Q2 2026, compared with $16.6B for Merck & Co.. Merck & Co. leads on revenue.
GSK's gross margin is 73.0% versus 73.5% for Merck & Co.. GSK's net margin is 5.2% versus -8.0% for Merck & Co..
Key differences
- Revenue growth from Q2 2025 to Q2 2026: GSK +5.3%, Merck & Co. +5.1%.
- GSK made an operating profit in its latest quarter (5.7% margin); Merck & Co. made an operating loss (-4.1%).
- GSK's KPIs on Sterling include Arexvy Sales by Region (Quarterly) and HIV Franchise Sales (Quarterly).
- Merck & Co.'s KPIs on Sterling include Merck Animal Health Livestock vs Companion Animal (Quarterly) and Merck Gardasil China Sales as Printed.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, GSK, Merck & Co..| Metric | GSK | Merck & Co. |
|---|---|---|
| Market Cap | - | - |
| Revenue | $10.60B | $16.61B |
| Cost of Revenue | $2.85B | $4.39B |
| Gross Profit | $7.74B | $12.21B |
| Operating Income | $606.00M | $-683.00M |
| Net Income | $548.00M | $-1.33B |
| R&D Expense | $4.37B | $9.74B |
| Earnings Per Share | $0.28 | -$0.54 |
| Gross Margin | 73.0% | 73.5% |
| Operating Margin | 5.7% | -4.1% |
| Net Profit Margin | 5.2% | -8.0% |
| Free Cash Flow | $2.78B | $4.48B |
| Cumulative Free Cash Flow | $157.21B | $249.70B |
| Operating Cash Flow | $3.19B | $5.37B |
| Cash & Equivalents | $3.89B | $6.85B |